Hepatitis G virus in clotting factor concentrates.
Blood-borne hepatitis is a well-known complication in patients with bleeding disorders. A recently discovered parentally transmitted virus, hepatitis G [GB virus C (GBV-C)] has an increased prevalence in patients with haemophilia. Clotting factor concentrates derived from pools of human plasma currently undergo viral inactivation techniques known to be effective against hepatitis B, C and HIV; however, the effectiveness of current purification and viral inactivation techniques against newly discovered viruses such as GBV-C is unknown. A total of 37 vials of clotting factor concentrates manufactured in the USA from 1981 to 1995 were tested for the presence of GBV-C virus. All samples that did not undergo a specific viral inactivation step were positive for GBV-C. Viral inactivation techniques that did not uniformly remove GBV-C included vapour heat treatment and dry heat treatments for less than 144 h. All samples treated by pasteurization, solvent detergent or dry heat for 144 h, were negative for the presence of GBV-C.
Alonso-Rubiano
E
E
Department of Pediatric Gastroenterology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Gerber
M
M
Friedman
P
P
Hodges
S
S
Leissinger
C
C
D017848:Blood-Borne Pathogens / Q000302:isolation & purification*; D002846:Chromatography, Affinity; D004340:Drug Contamination; D005164:Factor IX / Q000592:standards*; D005169:Factor VIII / Q000592:standards*; D029407:GB virus C / Q000302:isolation & purification*; D006801:Humans; D012367:RNA, Viral / Q000032:analysis; D013242:Sterilization / Q000379:methods; D038301:Virus Inactivation
D012367:RNA, Viral; D005169:Factor VIII; D005164:Factor IX